Prior Authorization Required

Many drugs listed on the CommunityCare ACA Drug List require Prior Authorization (PA), Step Therapy (ST), and/or Quantity Limits (QL). Providers must obtain PA where indicated before dispensing; failure to secure required PA, ST, or QL approval can result in claim denial or member liability. Follow product‑level requirements shown in the Requirements/Limits column (including PA, PA**, ST, QL, initial short‑term limits, loading dose allowances, and age‑based restrictions).

• Prior authorization required for high‑strength opioid formulations and certain branded products (PA flag shown next to product; example: high‑strength fentanyl patches, high‑strength oral opioids).
• PA required for many oncology, hematologic, and specialty agents; product entries often include PA plus specific QL (e.g., VENCLEXTA, KADCYLA, KEYTRUDA, REVLIMID, PADCEV, POMALYST, MEKINIST, etc.).
• PA and QL commonly apply to immunologic and other specialty biologics, self‑administered and physician‑administered (examples: many kinase inhibitors, somatostatin analogs, octreotide, lanreotide, pegvisomant, select MS, PAH, and pulmonary hypertension agents).
• PA required for select hepatitis B/C and high‑tier antiviral regimens (examples: EPCLUSA, HARVONI, SOVALDI, VOSEVI, VOSEVI, sofosbuvir products — many require ST + PA + QL where noted).
• Certain injectable antiretroviral kits and long‑acting HIV regimens require PA and have kit‑level QL and loading‑dose rules (examples: CABENUVA kit entries with PA, QL, and an allowed 30‑day loading dose kit).
• Some Parkinson disease products require PA and QL (example: INBRIJA caps — PA with QL 300 caps/30 days; ONGENTYS = PA).
• Specific products of note with PA or PA+QL: VIBERZI; selected hematologic agents (venetoclax/VENCLEXTA start pack and strength‑specific QL); deflazacort formulations noted with PA and QL in the Requirements/Limits column where listed.
• Age‑based restrictions and PA triggers: high‑risk medications (for example, nitrofurantoin formulations) require PA for members age 70 and older; other age or indication limits appear at the product level.
• Step therapy applies for many analgesics and other selected agents — ST entries on the chart indicate the member must try preferred agents first; examples include many opioid formulations and select sofosbuvir products.
• Quantity limits and initial short‑term limits are documented per product (examples: many opioid liquid/solid formulations are subject to initial 7‑day limits; lozenge, patch, vial, kit, and ampule QLs are specified per product).
• Documentation required for PA and exceptions: prescriber must submit supporting clinical statement and dosing documentation (including loading dose when applicable), dosing interval, and justification for QL/ST exceptions; expedited exception requests require clinician justification for faster review.
• Operational notes: IV ceftriaxone and other injectables may have initial course limits; physician‑administered immunologic agents often require PA/ST/QL and may have different step or prior authorization rules than self‑administered biologics.
• Triggers for denial: claims may be denied if PA/ST/QL requirements are not met, if prescriptions are not filled at a CommunityCare ACA network pharmacy when required, or if necessary documentation (including dosing interval, loading dose, or prescriber justification) is not provided.
• When requesting exceptions: expect to support QL and initial limits with clinical documentation; decisions are made within 72 hours once necessary information is received, or within 24 hours for approved expedited requests.
• Providers should consult the Requirements/Limits column for each product for exact PA, ST, QL, loading dose, kit frequency, and age‑based rules — this is the authoritative source for product‑level requirements.

Denial Risks if Authorization or Criteria Not Met

Failure to obtain required authorization, to satisfy step therapy, or to comply with quantity limits may result in denial of coverage or member financial responsibility. Claims for drugs that list PA, ST+PA, or QL in the Requirements/Limits column are subject to retrospective or prospective denial if criteria are not met.

• Denial triggers include: no prior authorization on file when PA is required; step therapy requirements not completed; quantity limits exceeded; prescriptions filled outside the CommunityCare ACA network when plan rules require in‑network pharmacy; missing clinical documentation (including dosing interval, loading dose, or prescriber statement).
• Some PA/ST requirements are strength‑specific — higher strengths may require PA even when lower strengths do not. If high‑strength flags appear (e.g., high‑strength fentanyl, hydrocodone, morphine, oxymorphone, tramadol, etc.), obtain PA before dispensing to avoid denial.
• PA/ST may apply differently to physician‑administered vs self‑administered products; ensure the correct route and billing pathway are used and that PA documentation reflects the administration setting.

Documentation Requirements for PA and Exceptions

Providers must submit clinical justification and supporting documentation when requesting PA or exceptions. For standard PA reviews, provide sufficient medical records, indication, prior medications tried (for ST), dosing regimen, and rationale for requested quantity or frequency. Expedited requests require explicit clinician justification of harm if delayed.

• Exception request documentation: prescriber statement supporting the exception; prior treatment history (to meet ST requirements); rationale for medical necessity when requesting overrides to QL or ST.
• Support for QL and initial limits: document anticipated duration of therapy, planned dosing interval, and any loading doses. If a loading dose is expected (e.g., CABENUVA, certain biologics), include the intended loading kit and timing in the request.
• General PA documentation: include diagnosis, prior therapies and responses, contraindications or intolerance to preferred agents, weight/age when relevant (age‑based vaccine or high‑risk med rules), and anticipated quantity or number of kits/vials per period.
• PA/QL documentation for self‑administered biologics and physician‑administered immunologics: include dosing schedule, injection frequency, number of pens/vials per fill, and site of administration if relevant. Many biologics also require QL supporting documentation.
• Folic acid and other supportive QLs: confirm eligibility or concurrent therapy where QLs are tied to specific indications. For example, folic acid QLs may be linked to disease‑specific eligibility; provide supporting diagnoses.
• IV ceftriaxone and other limited‑course injectables: document the intended initial course length and indicate if subsequent courses are planned; initial course limits are enforced unless additional clinical justification is supplied.

Step Therapy Requirements

Step therapy is required for many drug classes. When ST is listed, the member must have trials of preferred agents (documented) before a non‑preferred agent will be approved. Some physician‑administered agents also have step requirements.

• Step therapy common across many analgesics and other classes — examples include numerous opioid formulations that show ST plus initial 7‑day limits.
• Step therapy applies to select sofosbuvir/antiviral products and certain endocrine and antidiabetic combinations (entries showing ST; PA** indicates a combined ST+PA workflow).
• Where step therapy is present, providers should submit prior treatment history and evidence of failure, intolerance, or contraindication to preferred agents when requesting exceptions.